Troriluzole (hydrochloride)

Troriluzole hydrochloride is a third-generation peptide precursor of Riluzole (HY-B0211) and is an orally active glutamate modulator. Troriluzole hydrochloride can reduce synaptic glutamate levels and enhance the uptake of synaptic glutamate. Troriluzole hydrochloride shows potential for treating Alzheimer's disease and Generalized Anxiety Disorder (GAD) [1][2].

Product Specifications

CAS Number

[1926204-76-3]

Product Name Alternative

BHV-4157 (hydrochloride)

UNSPSC

12352005

Target

MGluR

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O=C(CN(C)C(CNC(CN)=O)=O)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1.Cl

Molecular Formula

C15H17ClF3N5O4S

Molecular Weight

455.84

References & Citations

[1]Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD) . Expert Opin Investig Drugs. 2019 Nov;28 (11) :1003-1012.|[2]Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27 (1) :18.